Depression accounted for an 8.7% share of the global clinical trials within the Central Nervous System therapy area in 2021, registering an increase of 1.3% when compared with the last ten-year average of 7.4% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Depression
Industry sponsored trials held a 38.3% share of all the clinical trials for Depression indication in 2021, registering an increase of 5.0% when compared with the ten-year average of 33.3%. Non-industry sponsored trials accounted for a 61.7% share in 2021, marking a decrease of 5.0% over the ten-year average of 66.7%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Depression trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Depression trials, accounting for a 50.0% share in 2021, when compared with the five-year average of 52.4% and ten-year average of 43.0%.
Europe was at the second position with a 26.3% share in 2021, over the five-year average of 29.5% and ten-year average of 35.2%, followed by North America with a 25.0% share in 2021, as against five-year and ten-year averages of 33.4% and 41.0% respectively.
Middle East and Africa stood fourth with a 7.5% share in 2021, compared with the five-year average of 5.1% and ten-year average of 3.9%, followed by South and Central America with a 5.6% share in 2021, over five-year and ten-year averages of 3.8% and 5.7% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Depression trials, accounting for a 31.9% share in 2021, as against the five-year average of 30.7% and ten-year average of 18.0%.
The US held a 22.5% share in 2021, over the five-year average of 32.4% and ten-year average of 39.7%, followed by Russia with a 16.3% share in 2021, compared with the five-year and ten-year averages of 9.7% and 12.5% respectively.
Japan held a 6.3% share in 2021, as against the five-year average of 6.5% and ten-year average of 7.8%.
Germany held a 5.0% share in 2021, over the five-year and ten-year averages of 8.9% and 11.0% respectively.
Top regions of non-industry sponsored Depression trials
Asia-Pacific was the top region for non-industry sponsored Depression trials, accounting for a 45.6% share in 2021 when compared with the five-year average of 40.1% and ten-year average of 35.0%.
North America was at the second position with a 20.1% share in 2021, over the five-year and ten-year averages of 25.8% and 30.8% respectively, followed by Europe with a 17.0% share in 2021, as against the five-year average of 13.1% and ten-year average of 14.4%.
Middle East and Africa stood at the fourth position with a 17.0% share in 2021, compared with the five-year average of 20.2% and ten-year average of 19.1%, followed by South and Central America with a 0.4% share in 2021, over the five-year and ten-year averages of 1.4% and 1.9% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Depression trials, accounting for a 34.4% share in 2021, as against the five-year average of 22.3% and ten-year average of 15.9%.
The US held a 14.7% share in 2021, over the five-year average of 22.6% and ten-year average of 26.4%, followed by Iran with a 14.3% share, compared with the five-year and ten-year averages of 18.4% and 17.3% respectively.
Canada held a 5.0% share in 2021, as against the five-year average of 3.2% and ten-year average of 4.5%.
Australia held a 3.9% share in 2021, over the five-year average of 2.7% and ten-year average of 3.4%.
Phase I trials lead industry sponsored clinical trials for Depression in 2021
Phase I trials held a 64.9% share of industry sponsored clinical trials for Depression in 2021, over the five-year average of 51.2% and ten-year average of 49.0%.
Phase II trials held a 16.7% share in 2021, as against the five-year average of 19.3% and ten-year average of 17.7%. Phase III trials held an 11.3% share in 2021, compared with the five-year and ten-year averages of 19.0% and 22.8% respectively.
Phase IV trials held a 7.1% share in 2021, over the five-year average of 10.6% and ten-year average of 10.5%.
Phase II trials lead non-industry sponsored clinical trials for Depression in 2021
Phase II trials held a 36.9% share of non-industry sponsored clinical trials for Depression in 2021, over the five-year average of 42.7% and ten-year average of 44.4%.
Phase IV trials held a 23.2% share in 2021, as against the five-year average of 25.0% and ten-year average of 27.2%. Phase I trials held a 21.4% share, compared with the five-year and ten-year averages of 11.9% and 10.3% respectively.
Phase III trials held a 18.5% share in 2021, over the five-year average of 20.3% and ten-year average of 18.1%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
